Akebia Therapeutics (AKBA) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $540000.0.
- Akebia Therapeutics' Net Income towards Common Stockholders rose 10269.47% to $540000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 6541.79%. This contributed to the annual value of -$69.4 million for FY2024, which is 3367.36% down from last year.
- Latest data reveals that Akebia Therapeutics reported Net Income towards Common Stockholders of $540000.0 as of Q3 2025, which was up 10269.47% from $247000.0 recorded in Q2 2025.
- Akebia Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $29.4 million during Q2 2022, with a 5-year trough of -$83.0 million in Q2 2021.
- Its 5-year average for Net Income towards Common Stockholders is -$25.9 million, with a median of -$18.0 million in 2024.
- As far as peak fluctuations go, Akebia Therapeutics' Net Income towards Common Stockholders skyrocketed by 13546.45% in 2022, and later crashed by 381400.65% in 2024.
- Over the past 5 years, Akebia Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$70.4 million in 2021, then skyrocketed by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614000.0 in 2023, then tumbled by 3814.01% to -$22.8 million in 2024, then soared by 102.37% to $540000.0 in 2025.
- Its last three reported values are $540000.0 in Q3 2025, $247000.0 for Q2 2025, and $6.1 million during Q1 2025.